Prophylactic HPV vaccination: past, present, and future - CORRIGENDUM.
نویسندگان
چکیده
1. Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiology and Infection 2016; 144: 449–468. doi:10.1017/S0950268815002198. Published online: 2 October 2015. Fig. 1. A comparison of vaccine efficacy against targeted HPV type-related (purple bars) and all cervical precancer (CIN2, CIN3, or AIS) (orange bars) by 2vHPV [27], and 4vHPV [28], for the HPV-naive populations (TVC-naive and ATP, respectively) and the entire vaccinated cohort (TVC and ITT, respectively). TVC, Total vaccine cohort; ATP, attention to protocol; ITT, intention to treat. Epidemiol. Infect. (2016), 144, 2472. © Cambridge University Press 2016 doi:10.1017/S0950268816000777
منابع مشابه
Vaccination against HPV: indications for women and the impact on the cervical screening programme.
A novel approach for primary prevention of cervical cancer has become available by the discovery of efficient prophylactic human papillomavirus (HPV) vaccines based on virus-like particles. This review elaborates on the progress in the field of prophylactic HPV vaccination achieved in the past decade, provides indications for prophylactic HPV vaccination, and discusses the impact on public heal...
متن کاملReview of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
The recognition of a strong etiological relationship between infection with high-risk human papillomavirusses and cervical cancer has prompted research to develop and evaluate prophylactic and therapeutic vaccines. One prophylactic quadrivalent vaccine using L1 virus-like particles (VLP) of HPV 6, 11, 16 and 18 is available on the European market since the end of 2006 and it is expected that a ...
متن کاملVaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives.
UNLABELLED Background Men and women with HIV infection are at increased risk of developing cancers associated with human papillomavirus (HPV). The two licensed prophylactic HPV vaccines protect against de novo infection with HPV-16 and HPV-18, which cause the majority of HPV-associated cancers. Currently, no vaccine efficacy data are available for persons with HIV infection. Nevertheless, some ...
متن کاملPast and future of prophylactic ablation of the cervical squamocolumnar junction
HPV vaccination has the potential to prevent the vast majority of cervical cancer cases but cervical cancer screening remains the only prevention strategy in adult unvaccinated women. The range of primary screening tests has expanded to include, in addition to cytology, visual inspection with acetic acid (VIA) and HPV-testing. HPV-testing has the best sensitivity and negative predictive value, ...
متن کاملPreliminary HPV vaccine results for women older than 25 years.
After prophylactic human papillomavirus (HPV) vaccina tion, cost-effectiveness models predict that a reduction in cervical cancer will occur decades from now, but only when 90% of all girls aged 11–12 years have been vaccinated for many years, assuming vaccines confer lifelong protection. Should prophylactic vaccination protect women for less than 15 years, the incidence of cervical cancer will...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Epidemiology and infection
دوره 144 11 شماره
صفحات -
تاریخ انتشار 2016